Delay or Avoidance of Total Hip Replacement

Damaged cartilage has limited capacity to heal itself. If left untreated, the damage can worsen over time. With minimally invasive arthroscopic treatment approaches for chondral defects in the hip, preserving the hip-joint cartilage and delaying or possibly even avoiding total hip replacement surgery is now possible.

Benefits

With its specially designed bilayer structure, Chondro-Gide® provides a protective environment that fosters the growth of new cartilage.

• Bio-derived, bilayer Collagen I/III membrane
• Biocompatible and naturally resorbed
• Easy to handle: supple and tear-resistant
• Can be glued or sutured into place
• Compatible with a range of tissue regeneration techniques
• One-step procedure
• Ready for use off the shelf

How Chondro-Gide® Works

Chondro-Gide® provides a protective cover and keeps in place cells released from the bone or introduced into a defect. It complements regenerative treatment approaches for chondral and osteochondral lesions. Whilst enveloping the defect and the cells within it during the initial stages of the healing process, Chondro-Gide® resorbs over approximately 4 months and is replaced by native tissue.

Clinical Evidence

Long-Term Advantages of AMIC® Chondro-Gide® vs. MFx Alone

The use of Chondro-Gide® in the hip is well established. Data up to 8 years post-op clearly demonstrates the long-term advantages of AMIC® Chondro-Gide® compared to MFx alone in acetabular defects. In a study comparing arthroscopic MFx alone with AMIC® Chondro-Gide®, De Girolamo et al. investigated 109 patients with chondral defects in the hip associated with FAI, treated with either AMIC® Chondro-Gide® or MFx. There was no significant difference in age or average defect size between the two patient groups. AMIC® results remained stable up to 8 years, whilst MFx results worsened after 2 years.

Sustained 5-Year Benefit vs. MFx

Fontana and De Girolamo (2015) demonstrated sustained 5-year benefit of AMIC® Chondro-Gide® for femoroacetabular impingement-induced chondral lesions compared with microfracture treatment.

Up to 9 Years Follow-Up with BMAC Enhancement

De Girolamo et al. (2019) showed that both standard AMIC® and AMIC® enhanced by autologous concentrated bone marrow aspirate (BMAC) allow for stable clinical and functional improvements at up to 9 years follow-up in a randomised controlled study.

AMIC® vs MACI®

A 5-year study by Mancini and Fontana compared AMIC® Chondro-Gide® with matrix-induced autologous chondrocyte implantation (MACI) for the treatment of medium-sized acetabular chondral defects. AMIC® offers additional benefits as a single-step, minimally invasive procedure that can reduce total treatment time and minimise morbidity.